ERCP - Endoscopic Retrograde Cholangiopancreatography — Cost, Top Hospitals & Success Rates | MyMedicPlus

Endoscopic Retrograde Cholangiopancreatography (ERCP) is a specialised procedure that uses a combination of flexible endoscopy and live X-ray imaging (fluoroscopy) to examine, diagnose, and treat conditions affecting the bile ducts, gallbladder, and pancreatic ducts. The word "retrograde" refers to the direction of contrast dye injection — upward (retrograde) into the ductal systems, against the normal flow of bile and pancreatic juice.

ERCP is performed using a side-viewing duodenoscope — a long, flexible, illuminated camera with a dedicated working channel — passed through the mouth, oesophagus, stomach, and into the first part of the small intestine (duodenum). The endoscopist locates the ampulla of Vater, the small papillary opening where the bile duct and pancreatic duct drain into the duodenum. A thin cannula is guided through the scope into the papilla, contrast dye is injected, and fluoroscopic X-ray images are obtained in real time to outline the ductal anatomy and reveal abnormalities such as stones, strictures, or leaks.

ERCP has two distinct roles. In its diagnostic role, it provides detailed ductal imaging. However, since non-invasive MRCP (Magnetic Resonance Cholangiopancreatography) and endoscopic ultrasound (EUS) now offer equivalent or superior diagnostic accuracy without procedural risk, purely diagnostic ERCP has been largely replaced. Today, ERCP is performed almost exclusively in its therapeutic role — when a definitive treatment such as stone extraction, stent placement, or sphincterotomy is planned based on prior imaging.

ERCP was first performed in 1968 by William McCune, and its therapeutic applications were rapidly developed through the 1970s. It is now one of the most commonly performed advanced endoscopic procedures worldwide, conducted in endoscopy units by specialist gastroenterologists or hepatobiliary surgeons trained in advanced therapeutic endoscopy. The procedure is well established, evidence-based, and endorsed by all major international gastroenterological societies.

ERCP is used both to confirm diagnoses and to treat a broad range of biliary and pancreatic disorders in the same sitting:

• Gallstones in the Common Bile Duct (Choledocholithiasis): The most common indication. Gallstones that have migrated from the gallbladder into the common bile duct cause jaundice, pain, and infection. ERCP allows removal of these stones by sphincterotomy and balloon or basket extraction without abdominal surgery.
• Acute Cholangitis: A severe bacterial infection of the bile duct requiring urgent biliary decompression. ERCP is the preferred urgent intervention, recommended within 24 to 72 hours by international cholangitis guidelines (Tokyo Guidelines 2018).
• Primary Sclerosing Cholangitis (PSC): A chronic inflammatory disease causing biliary strictures. ERCP is used to identify dominant strictures, obtain brush cytology for cholangiocarcinoma surveillance, and place stents to relieve dominant obstruction.
• Biliary Strictures: Narrowings from any cause — post-surgical, inflammatory, or malignant — are imaged, sampled, and treated by balloon dilation and stent placement to restore bile drainage.
• Pancreatic Strictures and Stones: In chronic pancreatitis, outflow obstruction from pancreatic ductal strictures or calculi causes recurrent severe pain. ERCP with pancreatic sphincterotomy, dilation, and stenting provides pain relief and prevents further ductal damage.
• Bile Leaks: Post-cholecystectomy or post-liver surgery bile leaks are effectively sealed by transpapillary biliary stenting, which reduces ductal pressure and allows spontaneous closure of the leak.
• Malignant Obstruction: Pancreatic cancer, cholangiocarcinoma, and periampullary tumours causing obstructive jaundice are palliated by metal stent insertion, restoring biliary drainage without surgery and enabling chemotherapy initiation.
• Intraductal Tissue Sampling: Brush cytology and forceps biopsy performed during ERCP provide tissue diagnosis from biliary strictures suspected to be malignant, where endoluminal sampling is otherwise impossible.

ERCP is appropriate for patients in whom clinical, biochemical, and imaging findings point to a biliary or pancreatic duct problem that requires direct endoscopic assessment or intervention. Selection criteria include:

• Prior Non-Invasive Imaging: Abdominal ultrasound, CT abdomen, or MRCP should be performed before ERCP whenever clinically possible. These confirm the indication and guide procedural planning. ERCP without prior imaging is reserved for emergencies (e.g., ascending cholangitis with shock).
• Clinical Indication: Typical presenting features include obstructive jaundice (yellow skin and eyes, dark urine, pale stools), right upper quadrant pain with dilated bile ducts on ultrasound, raised liver enzymes (bilirubin, alkaline phosphatase, GGT), or fever with biliary sepsis.
• Acceptable Procedural Risk: Patients must be fit enough for conscious sedation or anaesthetist-administered sedation. ERCP is routinely and safely performed in elderly patients, including those aged 80 and above, with careful risk stratification and sedation planning.
• Coagulation and Anticoagulation Management: Therapeutic ERCP procedures involving sphincterotomy require an INR below 1.5 and platelet count above 50,000. Blood thinners must be paused according to drug-specific bridge protocols agreed between the prescribing clinician and endoscopist.
• Accessible Anatomy: Standard ERCP requires an intact upper gastrointestinal anatomy. Patients who have had Roux-en-Y gastric bypass, Whipple procedure, or hepaticojejunostomy cannot undergo conventional ERCP and need device-assisted enteroscopy-ERCP or percutaneous alternatives at specialist centres.

ERCP is not indicated as a first-line investigation for unexplained abdominal pain without objective biliary or pancreatic imaging findings. In such cases, MRCP or EUS carries equivalent or superior diagnostic yield at lower procedural risk.

ERCP is performed in a dedicated endoscopy suite equipped with a fluoroscopy C-arm and radiolucent table. The standard procedure sequence is:

• Pre-Procedure Preparation: Patients fast for at least 6 hours beforehand. Blood tests (full blood count, coagulation, liver function, renal function) and informed consent are obtained. Antibiotic prophylaxis is given if biliary drainage may be incomplete. Rectal indomethacin 100 mg is commonly administered at this stage in eligible patients to reduce post-ERCP pancreatitis risk.
• Conscious Sedation: An intravenous cannula is placed and sedative medications — typically a combination of a benzodiazepine (midazolam) and an opioid analgesic (pethidine or fentanyl) — are administered. Some centres and higher-risk patients receive propofol-based deep sedation under anaesthesia supervision. Throat spray (lignocaine) may be used to suppress the gag reflex.
• Scope Insertion and Cannulation: The side-viewing duodenoscope is passed through the mouth into the duodenum. The endoscopist identifies the ampulla of Vater and selectively cannulates the bile duct or pancreatic duct using a soft-tipped cannula or a sphincterotome wire. This is the most technically demanding step and requires significant training and experience.
• Cholangiography and Pancreatography: Water-soluble iodinated contrast dye is injected through the cannula and fluoroscopic images are taken to outline the ductal anatomy and identify stones, strictures, leaks, or filling defects.
• Therapeutic Interventions: Based on findings, the endoscopist performs sphincterotomy, stone extraction with balloons or baskets, mechanical or laser lithotripsy, stent placement, biliary dilation, or tissue sampling — all through the working channel of the scope in the same session.
• Procedure Completion: After haemostasis is confirmed and all instruments are withdrawn, the scope is removed. Total procedure time is 30 to 90 minutes depending on complexity. The patient is transferred to the recovery area for monitoring.

The procedure is performed on a tilting radiolucent table with the patient positioned in the left lateral decubitus or prone position to optimise bile duct visualisation under fluoroscopy.

ERCP offers a combination of diagnostic precision and immediate therapeutic capability that no other single procedure matches for biliary and pancreatic disease:

• Single-Session Diagnosis and Treatment: Unlike MRCP or EUS which only diagnose, ERCP allows the endoscopist to confirm a finding (such as a common bile duct stone) and immediately remove it in the same session — avoiding a second procedure, anaesthesia, or surgical admission.
• Non-Surgical Access to the Bile Duct: ERCP reaches the bile duct through the natural gastrointestinal orifice without any incision, avoiding the morbidity, scarring, and prolonged recovery of open or even laparoscopic surgery for equivalent biliary conditions.
• High Technical Success Rate: Successful cannulation of the target duct is achieved in 90 to 95% of cases by experienced endoscopists at high-volume centres. Stone clearance rates exceed 90% for standard common bile duct stones.
• Life-Saving in Biliary Sepsis: In acute cholangitis — a biliary emergency with mortality rates up to 10 to 20% if untreated — emergency ERCP for biliary drainage is the standard of care and reduces mortality significantly compared to surgery or conservative management alone.
• Outpatient or Short-Stay Procedure: The majority of ERCPs are performed as day-case procedures or with an overnight stay, enabling rapid discharge and reduced healthcare costs compared to equivalent surgical procedures requiring general anaesthesia and multi-day admission.
• Palliation of Malignant Obstruction: For patients with inoperable biliary or pancreatic cancers causing obstructive jaundice, metal stent placement via ERCP restores bile flow, reduces jaundice and itch, improves quality of life, and allows systemic chemotherapy to commence.
• Tissue Diagnosis: Intraductal brush cytology and forceps biopsy via ERCP provide tissue samples for histological diagnosis from biliary strictures that cannot be sampled by any other percutaneous means.

ERCP has a recognised complication rate of 3 to 10%, making thorough pre-procedure counselling and meticulous patient selection essential. Major risks include:

• Post-ERCP Pancreatitis (PEP): Occurring in 3 to 5% of average-risk patients, PEP is the most common serious complication. Risk is higher in younger women, patients with prior PEP, suspected sphincter of Oddi dysfunction, and cases requiring multiple pancreatic duct contrast injections or repeated cannulation attempts. Evidence-based prevention: rectal indomethacin 100 mg post-procedure reduces PEP risk by approximately 50%; prophylactic pancreatic duct stenting is added in the highest-risk patients.
• Bleeding: Post-sphincterotomy bleeding occurs in 1 to 2% of therapeutic ERCPs. Risk is higher with anticoagulant use, coagulopathy, portal hypertension, and low platelet count. Most bleeding is managed endoscopically at the time of the procedure or on delayed presentation; surgical or angiographic intervention is rarely required.
• Infection and Cholangitis: Inadequate biliary drainage post-ERCP allows bacterial proliferation in a contrast-filled duct, causing cholangitis. Prophylactic antibiotics are given when complete drainage is not achieved, and patients are monitored for fever post-discharge.
• Perforation: Duodenal perforation or retroperitoneal perforation from sphincterotomy occurs in under 1% of cases. Endoscopic clip closure is attempted for small defects; large perforations with contamination require emergency surgical repair.
• Sedation-Related Events: Cardiorespiratory depression from sedative medications is possible, particularly in elderly patients and those with obstructive sleep apnoea. Continuous pulse oximetry and oxygen supplementation are standard; resuscitation equipment must be immediately available.
• Radiation Exposure: Fluoroscopic imaging involves ionising radiation. ERCP rooms should use digital subtraction with dose-reduction protocols. Cumulative exposure should be recorded, particularly for patients requiring multiple ERCP procedures over time.

Overall procedure-attributable 30-day mortality for elective ERCP is below 0.5%. In emergency cholangitis, mortality is primarily determined by the severity of sepsis rather than the procedure itself.

Recovery from ERCP is typically rapid. The following guidance applies to most patients after an uncomplicated procedure:

• Immediate Recovery: Patients are monitored for 2 to 4 hours post-procedure for vital sign stability, abdominal pain, and return of full consciousness. In high-risk patients, serum amylase is checked before discharge. Any fever, significant abdominal pain, or haemodynamic instability prompts hospital admission for observation.
• Oral Intake: Sips of water are permitted 1 to 2 hours post-procedure when the patient is alert and comfortable. Light food is usually tolerated by the same evening, with return to normal diet within 24 hours in uncomplicated cases.
• Discharge Instructions: Patients must be accompanied home by a responsible adult and must not drive or operate machinery for 24 hours following sedation. Written post-procedure instructions detailing warning signs and emergency contact numbers are provided at discharge.
• Medications After ERCP: Non-steroidal anti-inflammatory drugs (NSAIDs) are avoided for 5 to 7 days after sphincterotomy to reduce delayed bleeding risk. Anticoagulants are restarted at 5 to 7 days post-sphincterotomy under clinician guidance. Routine acid suppression with a proton pump inhibitor is sometimes prescribed for 2 to 4 weeks post-sphincterotomy to promote healing.
• Stent and Procedure Follow-Up: Patients with plastic biliary stents require return ERCP for stent exchange every 3 to 6 months. A clinic review at 4 to 6 weeks after ERCP is standard for stone clearance confirmation (imaging) and liver function test normalisation.
• Warning Symptoms: Patients should seek emergency care for fever above 38.5 degrees Celsius, worsening abdominal or back pain, jaundice, dark urine, pale stools, or vomiting blood — all potential signs of post-ERCP complications including pancreatitis, cholangitis, bleeding, or perforation.

ERCP costs depend on the country, the clinical indication, the hospital facility level, and whether a diagnostic or complex therapeutic procedure is required.

• Country Variation: In the United States, a single ERCP procedure costs USD 8,000 to 15,000 including facility fees. In India, Thailand, and Malaysia, equivalent quality ERCP at JCI-accredited tertiary hospitals costs USD 1,500 to 4,000. Eastern European centres (Poland, Hungary, Czech Republic) offer ERCP at USD 2,000 to 5,000. Medical tourism for elective therapeutic ERCP generates typical savings of 60 to 80%.
• Diagnostic versus Therapeutic ERCP: A purely diagnostic ERCP (cholangiography alone) is less expensive than a therapeutic session involving stone removal, stenting, or lithotripsy, which requires additional procedural time, specialist accessories, and often a longer observation period.
• Stent Selection: Plastic stents are inexpensive (USD 50 to 200) but must be exchanged every 3 to 6 months, incurring repeat procedure costs. Metal stents (USD 800 to 2,500 each) have longer patency but are appropriate only in specific clinical contexts.
• Sedation Model: Endoscopist-administered conscious sedation is the least costly. Cases requiring monitored anaesthesia care or general anaesthesia add USD 500 to 1,500 to the procedural cost and require an anaesthesiology team.
• Admission Duration: Day-case ERCP is significantly less expensive than inpatient admission. Complications extending hospital stay substantially increase the episode cost. Booking at experienced high-volume centres reduces complication risk and associated downstream costs.
• Insurance and Pre-Authorisation: ERCP for medically documented indications (CBD stones, cholangitis, malignant obstruction) is typically covered by health insurance plans in most countries. International health insurance policies should be checked for coverage of treatment at overseas facilities before arranging medical travel.

Use MyMedicPlus to compare ERCP pricing at accredited hospitals across more than 40 countries and request personalised quotes from verified gastroenterology teams.

Several alternatives to ERCP exist for both diagnostic assessment and therapeutic management of biliary and pancreatic disease:

• MRCP (Magnetic Resonance Cholangiopancreatography): The preferred non-invasive alternative to diagnostic ERCP. MRCP provides high-resolution imaging of bile ducts and pancreatic ducts without sedation, radiation, or procedural risk. It has sensitivity of 90 to 95% for common bile duct stones and is the first-line investigation for suspected biliary obstruction. It cannot, however, perform any therapeutic interventions.
• Endoscopic Ultrasound (EUS): A minimally invasive endoscopic procedure using ultrasound imaging from within the gastrointestinal tract. EUS provides highly accurate assessment of CBD stones (sensitivity greater than 95%), biliary stricture characteristics, and pancreatic pathology. EUS-guided fine needle aspiration (FNA) provides tissue diagnosis from periductal masses without radiation. EUS-guided biliary drainage is an emerging alternative when ERCP fails.
• Laparoscopic Common Bile Duct Exploration (LCBDE): Performed concurrently with laparoscopic cholecystectomy. LCBDE achieves CBD stone clearance rates equivalent to ERCP in experienced surgical centres and avoids the need for a separate endoscopic procedure. It is preferred when ERCP has failed or when gallbladder removal is already planned.
• Percutaneous Transhepatic Biliary Drainage (PTBD): A radiology-guided alternative for biliary decompression when ERCP is technically impossible due to altered upper gastrointestinal anatomy, duodenal obstruction, or failed ERCP cannulation. A needle is passed through the skin into dilated bile ducts under ultrasound guidance to drain bile externally or place an internal stent anterograde.
• Surgery (Choledochotomy or Hepaticojejunostomy): Open or laparoscopic surgical common bile duct exploration and biliary reconstruction (hepaticojejunostomy) are reserved for cases where endoscopic and percutaneous approaches have failed or where complex biliary reconstruction is required following stricture, trauma, or malignancy.
• Observation and Medical Therapy: For small CBD stones (under 6 mm) in asymptomatic patients, watchful waiting with ursodeoxycholic acid may be considered. Spontaneous stone passage occurs in a proportion of cases, though recurrence and symptom progression are the more common natural history without definitive clearance.